AIMS: The INSPIRON-I trial is a first-in-man evaluation of the safety and efficacy of the Inspiron drug-eluting stent, a sirolimus-eluting stent with abluminal biodegradable polymer coating and thin cobalt-chromium alloy. METHODS AND RESULTS: This is a randomised, multicentre comparison between Inspiron and a stent with the same metallic structure but without polymer coating or drug elution (Cronus). The primary objective was to evaluate the in-segment late loss (LLL) at six months. Secondary endpoints included percent in-stent obstruction as measured by intravascular ultrasound (IVUS) at six months and major adverse cardiac events (MACE). Fifty-eight patients were enrolled (60 lesions), 39 for Inspiron and 19 for Cronus. Baseline clinical and angiographic characteristics of both groups were similar. At six months, the in-segment LLL was reduced in the Inspiron group compared to the control group (0.19±0.16 mm vs. 0.58±0.4 mm, respectively; p<0.001), as well as the percent neointimal obstruction (7.8±7.1% vs. 26.5±11.4%; p<0.001). At two-year follow-up, incidence of MACE was similar between groups (7.9 vs. 21.1%, respectively; p=0.20), with lower target lesion revascularisation for Inspiron (0 vs. 21.1%, respectively; p=0.01) and no stent thrombosis. CONCLUSIONS:Sirolimus eluted from an abluminal biodegradable polymer on a cobalt-chromium alloy proved effective in reducing restenosis at six months.
RCT Entities:
AIMS: The INSPIRON-I trial is a first-in-man evaluation of the safety and efficacy of the Inspiron drug-eluting stent, a sirolimus-eluting stent with abluminal biodegradable polymer coating and thin cobalt-chromium alloy. METHODS AND RESULTS: This is a randomised, multicentre comparison between Inspiron and a stent with the same metallic structure but without polymer coating or drug elution (Cronus). The primary objective was to evaluate the in-segment late loss (LLL) at six months. Secondary endpoints included percent in-stent obstruction as measured by intravascular ultrasound (IVUS) at six months and major adverse cardiac events (MACE). Fifty-eight patients were enrolled (60 lesions), 39 for Inspiron and 19 for Cronus. Baseline clinical and angiographic characteristics of both groups were similar. At six months, the in-segment LLL was reduced in the Inspiron group compared to the control group (0.19±0.16 mm vs. 0.58±0.4 mm, respectively; p<0.001), as well as the percent neointimal obstruction (7.8±7.1% vs. 26.5±11.4%; p<0.001). At two-year follow-up, incidence of MACE was similar between groups (7.9 vs. 21.1%, respectively; p=0.20), with lower target lesion revascularisation for Inspiron (0 vs. 21.1%, respectively; p=0.01) and no stent thrombosis. CONCLUSIONS:Sirolimus eluted from an abluminal biodegradable polymer on a cobalt-chromium alloy proved effective in reducing restenosis at six months.
Authors: Guy F A Prado; Expedito E Ribeiro; Pedro H M C Melo; Fabio A Pinton; Antonio Esteves-Filho; Celso K Takimura; Jose Mariani; Luiz J Kajita; Gilberto Marchiori; Breno de Alencar Araripe Falcao; Micheli Z Galon; Paulo R Soares; Silvio Zalc; Pedro A Lemos Journal: Cardiovasc Diagn Ther Date: 2015-12
Authors: Julio F Marchini; Wilton F Gomes; Bruno Moulin; Marco A Perin; Ludmilla A R R Oliveira; J Airton Arruda; Valter C Lima; Antonio A G Lima; Paulo R A Caramori; Cesar R Medeiros; Mauricio R Barbosa; Fabio S Brito; Expedito E Ribeiro; Pedro A Lemos Journal: Cardiovasc Diagn Ther Date: 2014-12
Authors: Marcos Danillo Peixoto Oliveira; Expedito E Ribeiro; Carlos M Campos; Henrique B Ribeiro; Bruno L R Faillace; Augusto C Lopes; Rodrigo B Esper; George X Meirelles; Marco A Perin; Alexandre Abizaid; Pedro A Lemos Journal: Cardiovasc Diagn Ther Date: 2015-08
Authors: J Ribamar Costa; Daniel Chamié; Alexandre A C Abizaid; Expedito Ribeiro; George C Meireles; Maurício Prudente; Carlos A Campos; Juliana P Castro; Ricardo Costa; Pedro A Lemos Journal: Int J Cardiovasc Imaging Date: 2016-10-06 Impact factor: 2.357
Authors: Abhilash Akinapelli; Jack P Chen; Kristine Roy; Joseph Donnelly; Keith Dawkins; Barbara Huibregtse; Dongming Hou Journal: Curr Cardiol Rev Date: 2017
Authors: Raffaele Piccolo; Kaare H Bonaa; Orestis Efthimiou; Olivier Varenne; Philip Urban; Christoph Kaiser; Lorenz Räber; Adam de Belder; Wouter Remkes; Arnoud W J Van't Hof; Goran Stankovic; Pedro A Lemos; Tom Wilsgaard; Jörg Reifart; Alfredo E Rodriguez; Expedito E Ribeiro; Patrick W J C Serruys; Alex Abizaid; Manel Sabaté; Robert A Byrne; Jose M de la Torre Hernandez; William Wijns; Giovanni Esposito; Peter Jüni; Stephan Windecker; Marco Valgimigli Journal: J Am Heart Assoc Date: 2021-10-08 Impact factor: 5.501